These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 28277988)
1. Therapy Rationale for Mineralocorticoid-Receptor Antagonists, Acetazolamide and a Switch of Therapy in Nonresponders in Central Serous Chorioretinopathy. Rübsam A; Thieme CE; Schlomberg J; Winterhalter S; Müller B; Joussen AM; Stübiger N J Ocul Pharmacol Ther; 2017 Apr; 33(3):141-148. PubMed ID: 28277988 [TBL] [Abstract][Full Text] [Related]
2. CENTRAL SEROUS CHORIORETINOPATHY TREATED WITH MINERALOCORTICOID ANTAGONISTS: A ONE-YEAR PILOT STUDY. Ghadiali Q; Jung JJ; Yu S; Patel SN; Yannuzzi LA Retina; 2016 Mar; 36(3):611-8. PubMed ID: 26405766 [TBL] [Abstract][Full Text] [Related]
3. Mineralocorticoid receptor antagonism in the treatment of chronic central serous chorioretinopathy: a pilot study. Bousquet E; Beydoun T; Zhao M; Hassan L; Offret O; Behar-Cohen F Retina; 2013; 33(10):2096-102. PubMed ID: 23719402 [TBL] [Abstract][Full Text] [Related]
4. [Eplerenone treatment in chronic central serous chorioretinopathy]. Sampo M; Soler V; Gascon P; Ho Wang Yin G; Hoffart L; Denis D; Matonti F J Fr Ophtalmol; 2016 Jun; 39(6):535-42. PubMed ID: 27230892 [TBL] [Abstract][Full Text] [Related]
5. SPIRONOLACTONE FOR NONRESOLVING CENTRAL SEROUS CHORIORETINOPATHY: A RANDOMIZED CONTROLLED CROSSOVER STUDY. Bousquet E; Beydoun T; Rothschild PR; Bergin C; Zhao M; Batista R; Brandely ML; Couraud B; Farman N; Gaudric A; Chast F; Behar-Cohen F Retina; 2015 Dec; 35(12):2505-15. PubMed ID: 26017871 [TBL] [Abstract][Full Text] [Related]
6. Oral Mineralocorticoid-Receptor Antagonists: Choroidal Parameters Changes Using OCT in Central Serous Chorioretinopathy. Faghihi H; Mohammadzadeh V; Nabavi A; Faghihi S; Kadivar S; Ghassemi F Ophthalmic Surg Lasers Imaging Retina; 2019 Nov; 50(11):726-733. PubMed ID: 31755972 [TBL] [Abstract][Full Text] [Related]
7. Mineralocorticoid Receptor Antagonists in Central Serous Chorioretinopathy: A Meta-Analysis of Randomized Controlled Trials. Wang SK; Sun P; Tandias RM; Seto BK; Arroyo JG Ophthalmol Retina; 2019 Feb; 3(2):154-160. PubMed ID: 31014765 [TBL] [Abstract][Full Text] [Related]
8. MINERALOCORTICOID RECEPTOR ANTAGONIST TREATMENT IN BILATERAL CHRONIC CENTRAL SEROUS CHORIORETINOPATHY: A COMPARATIVE STUDY OF EXUDATIVE AND NONEXUDATIVE FELLOW EYES. Gergely R; Kovács I; Schneider M; Resch M; Papp A; Récsán Z; Nagy ZZ; Ecsedy M Retina; 2017 Jun; 37(6):1084-1091. PubMed ID: 27627749 [TBL] [Abstract][Full Text] [Related]
9. Effect of Acetazolamide on Choroidal Morphology in Central Serous Chorioretinopathy. Kwak JH; Hong SW; Ra H; Kim EC; Kang NY; Baek J Korean J Ophthalmol; 2019 Dec; 33(6):493-499. PubMed ID: 31833245 [TBL] [Abstract][Full Text] [Related]
10. Systemic Mineralocorticoid Antagonists in the Treatment of Central Serous Chorioretinopathy. Yang D; Eliott D Semin Ophthalmol; 2017; 32(1):36-42. PubMed ID: 27929707 [TBL] [Abstract][Full Text] [Related]
11. Clinical experience with eplerenone to treat chronic central serous chorioretinopathy. Cakir B; Fischer F; Ehlken C; Bühler A; Stahl A; Schlunck G; Böhringer D; Agostini H; Lange C Graefes Arch Clin Exp Ophthalmol; 2016 Nov; 254(11):2151-2157. PubMed ID: 27145785 [TBL] [Abstract][Full Text] [Related]
13. Eplerenone for the treatment of chronic central serous chorioretinopathy: 3-year clinical experience. Petkovsek DS; Cherfan DG; Conti FF; Hom GL; Ehlers JP; Babiuch AS; Rachitskaya AV; Kaiser PK; Schachat AP; Srivastava SK; Sharma S; Singh RP Br J Ophthalmol; 2020 Feb; 104(2):182-187. PubMed ID: 31079056 [TBL] [Abstract][Full Text] [Related]
14. A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROL PILOT STUDY OF EPLERENONE FOR THE TREATMENT OF CENTRAL SEROUS CHORIORETINOPATHY (ECSELSIOR). Rahimy E; Pitcher JD; Hsu J; Adam MK; Shahlaee A; Samara WA; Vander JF; Kaiser RS; Chiang A; Spirn MJ; Fineman MS Retina; 2018 May; 38(5):962-969. PubMed ID: 28426624 [TBL] [Abstract][Full Text] [Related]
15. Comparison of two mineralcorticosteroids receptor antagonists for the treatment of central serous chorioretinopathy. Pichi F; Carrai P; Ciardella A; Behar-Cohen F; Nucci P; Int Ophthalmol; 2017 Oct; 37(5):1115-1125. PubMed ID: 27757733 [TBL] [Abstract][Full Text] [Related]
16. Mineralocorticoid receptor antagonists in chronic central serous chorioretinopathy. Sanhueza A; González R Medwave; 2020 Sep; 20(8):e8036. PubMed ID: 33017387 [TBL] [Abstract][Full Text] [Related]
17. The use of mineralocorticoid receptor antagonists in chronic central serous chorioretinopathy. Pociej-Marciak W; Karska-Basta I; Ozog-Baran J; Kubicka-Trzaska A; Filemonowicz-Skoczek A; Romanowska-Dixon B Klin Oczna; 2016 Aug; 118(1):48-54. PubMed ID: 29715409 [TBL] [Abstract][Full Text] [Related]
18. [Treatment of central serous chorioretinopathy with mineralocorticoid receptor antagonists]. Cakir B; Agostini H; Lange C Ophthalmologe; 2019 Feb; 116(2):189-200. PubMed ID: 30255262 [TBL] [Abstract][Full Text] [Related]
19. Mineralocorticoid Antagonists in the Treatment of Central Serous Chorioretinopathy: A Comparative Analysis. Kapoor KG; Wagner AL Ophthalmic Res; 2016; 56(1):17-22. PubMed ID: 26982318 [TBL] [Abstract][Full Text] [Related]
20. A new treatment approach - Eplerenone - in central serous chorioretinopathy - Case report. Cioboata M; Alexandrescu C; Hopinca CA; Pienaru MC; Merticariu A; Schmitzer S J Med Life; 2016; 9(1):92-94. PubMed ID: 27713772 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]